Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ovarian Neoplasms

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 32 articles: HTML format

Single Articles

August 2024
1. FOULKES WD, Polak P
   Probing the relevance of BRCA1 and BRCA2 germline pathogenic variants beyond breast and ovarian cancer.
   J Natl Cancer Inst. 2024 Aug 22:djae184. doi: 10.1093.
   PubMed    
   
   
   
2. MYERS ER
   Reducing ovarian cancer mortality through screening: an impossible dream?
   J Natl Cancer Inst. 2024 Aug 12:djae175. doi: 10.1093.
   PubMed    
   
   
   
3. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
   Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
   J Natl Cancer Inst. 2024;116:1280-1287.
   PubMed     Abstract available
   
   
   July 2024
4. ISHIZAWA S, Niu J, Tammemagi MC, Irajizad E, et al
   Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework.
   J Natl Cancer Inst. 2024 Jul 23:djae145. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. ZHENG G, Baandrup L, Wang J, Hertzum-Larsen R, et al
   Ovarian cancer risk factors in relation to family history.
   J Natl Cancer Inst. 2024 Jul 4:djae164. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2024
6. BAKER SG, Etzioni R
   Prediagnostic evaluation of multicancer detection tests: design and analysis considerations.
   J Natl Cancer Inst. 2024;116:795-799.
   PubMed     Abstract available
   
   
   May 2024
7. DAVIS EW, Attwood K, Prunier J, Paragh G, et al
   The association of body composition phenotypes before chemotherapy with epithelial ovarian cancer mortality.
   J Natl Cancer Inst. 2024 May 28:djae112. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2024
8. CAO A, Esserman DA, Cartmel B, Irwin ML, et al
   Association between diet quality and ovarian cancer risk and survival.
   J Natl Cancer Inst. 2024 Feb 23:djae040. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2023
9. PHUNG MT, Lee AW, McLean K, Anton-Culver H, et al
   A framework for assessing interactions for risk stratification models: the example of ovarian cancer.
   J Natl Cancer Inst. 2023 Jul 12:djad137. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2023
10. HURWITZ LM, Dogbe N, Hughes Barry K, Koutros S, et al
    Obesity and prostate cancer screening, incidence, and mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2023 Jun 29:djad113. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. LI S, Nguyen-Dumont T, Southey MC, Hopper JL, et al
    RE: Heterozygous BRCA1 and BRCA2 and mismatch repair gene pathogenic variants in children and adolescents with cancer.
    J Natl Cancer Inst. 2023;115:757-759.
    PubMed    
    
    
    May 2023
12. SHI J, Kraft P, Rosner BA, Benavente Y, et al
    Risk prediction models for endometrial cancer: development and validation in an international consortium.
    J Natl Cancer Inst. 2023;115:552-559.
    PubMed     Abstract available
    
    
    April 2023
13. GUPTA S, Hanna PE, Ouyang T, Yamada KS, et al
    Kidney Function in Patients with Ovarian Cancer Treated with Poly (ADP-ribose) polymerase (PARP) Inhibitors.
    J Natl Cancer Inst. 2023 Apr 19:djad070. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2023
14. FOURNIER A, Cairat M, Severi G, Gunter MJ, et al
    Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study.
    J Natl Cancer Inst. 2023 Feb 21:djad035. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. EVANS DG, Woodward ER
    RE: Heterozygous BRCA1/BRCA2 and mismatch repair gene pathogenic variants in children and adolescents with cancer.
    J Natl Cancer Inst. 2023;115:224-225.
    PubMed    
    
    
    
16. MAJIDI A, Na R, Jordan SJ, DeFazio A, et al
    Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study.
    J Natl Cancer Inst. 2023 Feb 6:djac239. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2023
17. FU Z, Brooks MM, Irvin S, Jordan S, et al
    Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.
    J Natl Cancer Inst. 2023 Jan 23:djad011. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2022
18. SAFDAR NS, Stasenko M, Selenica P, Martin AS, et al
    Genomic Determinants of Early Recurrences in Low-Stage, Low-Grade Endometrioid Endometrial Carcinoma.
    J Natl Cancer Inst. 2022;114:1545-1548.
    PubMed     Abstract available
    
    
    October 2022
19. DEVRIES AA, Dennis J, Tyrer JP, Peng PC, et al
    Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
    J Natl Cancer Inst. 2022 Oct 10. pii: 6751998. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2022
20. 
    Correction to: Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older.
    J Natl Cancer Inst. 2022 Jun 17. pii: 6609827. doi: 10.1093.
    PubMed    
    
    
    April 2022
21. LEHRER S, Rheinstein PH
    RE: Nitrogen-Based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older.
    J Natl Cancer Inst. 2022 Apr 23. pii: 6572816. doi: 10.1093.
    PubMed    
    
    
    
22. SCHRIJVER LH, Mooij TM, Pijpe A, Sonke GS, et al
    Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    J Natl Cancer Inst. 2022;114:540-552.
    PubMed     Abstract available
    
    
    March 2022
23. TUESLEY KM, Webb PM, Protani MM, Spilsbury K, et al
    Nitrogen-Based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older.
    J Natl Cancer Inst. 2022 Mar 9. pii: 6545294. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2021
24. TAKAHASHI K
    Untangling the Relationship between Clonal Hematopoiesis and Ovarian Cancer Therapies.
    J Natl Cancer Inst. 2021 Dec 28. pii: 6486529. doi: 10.1093.
    PubMed    
    
    
    
25. WEBER-LASSALLE K, Ernst C, Reuss A, Mollenhoff K, et al
    Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients with Ovarian Cancer.
    J Natl Cancer Inst. 2021 Dec 28. pii: 6486427. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2021
26. DE SOUZA C, Madden J, Koestler DC, Minn D, et al
    Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer.
    J Natl Cancer Inst. 2021;113:1246-1257.
    PubMed     Abstract available
    
    
    August 2021
27. KURIAN AW, Abrahamse P, Bondarenko I, Hamilton AS, et al
    Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.
    J Natl Cancer Inst. 2021 Aug 9. pii: 6346986. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2021
28. CALLENS C, Vaur D, Soubeyran I, Rouleau E, et al
    Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
    J Natl Cancer Inst. 2021;113:917-923.
    PubMed     Abstract available
    
    
    March 2021
29. WENZEL L, Osann K, McKinney C, Cella D, et al
    Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.
    J Natl Cancer Inst. 2021 Mar 17. pii: 6174697. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2020
30. PERES LC, Bethea TN, Camacho TF, Bandera EV, et al
    Racial differences in population attributable risk for epithelial ovarian cancer in the OCWAA Consortium.
    J Natl Cancer Inst. 2020 Nov 30. pii: 6012358. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. SPAAN M, van den Belt-Dusebout AW, Lambalk CB, van Boven HH, et al
    Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology.
    J Natl Cancer Inst. 2020 Nov 17. pii: 5981708. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2020
32. YANG X, Song H, Leslie G, Engel C, et al
    Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D.
    J Natl Cancer Inst. 2020 Feb 28. pii: 5764125. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.